172
Participants
Start Date
December 7, 2019
Primary Completion Date
May 18, 2020
Study Completion Date
May 18, 2020
ZSP1273 200 mg
1 X 200-mg tablet taken orally
Placebo
2 tablets taken orally
ZSP1273-400 mg
2 X 200-mg tablet taken orally
Placebo
1 tablet taken orally
ZSP1273-600 mg
3 X 200-mg tablet taken orally
Placebo
3 tablets taken orally
Placebo
Subjects will receive matching placebo of ZSP1273
The Second Hospital Of Anhui Medical University, Hefei
Beijing Ditan Hospital Capital Medical University, Beijing
Beijing Luhe Hospital,Capital Medical University, Beijing
Peking University Third Hospital, Beijing
Zhongshan Hospital Xiamen University, Xiamen
Dongguan people's Hospital, Dongguan
Nanfang Hospital,South Medical Hospital, Guangzhou
The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou
Traditional Chinese Medicine Hospital of Guangdong Province, Guangzhou
Huizhou Municipal Central Hospital, Huizhou
Jieyang People's Hospital, Jieyang
Shenzhen People's Hospital, Shenzhen
Affiliated Hospital Of Guangdong Medical University, Zhanjiang
Henan Provincial People's Hospital, Zhengzhou
The Sixth People's Hospital Of Zhengzhou, Zhengzhou
Sir Run Run Hospital Nanjing Medical University, Nanjing
Jiujiang University Hospital, Jiujiang
The First Affiliated Hospital Of Nanchang University, Nanchang
Shengjing Hospital of China Medical University, Shenyang
Linyi People's Hospital, Linyi
Qingdao Municipal Hospital, Qingdao
First Hospital of Shanxi Medical University, Taiyuan
Chengdu Fifth People's Hospital, Chengdu
General Hospital, Tianjin Medical University, Tianjin
The First Affiliated Hospital,Zhejiang University, Hangzhou
Zhejiang Provincial People's Hospital, Hangzhou
Guangdong Raynovent Biotech Co., Ltd
INDUSTRY